Parkinson&rsquo;s disease Levodopa-induced Dyskinesia
Parkinson&rsquo;s disease (PD) is a life-threatening progressive neurodegenerative disease characterized by severe locomotor impairments, including bradykinesia, tremor, and rigidity. Other abnormalities associated with PD are cognitive defects, psychiatric abnormalities, and neurodegenerative implications of levodopa-induced dyskinesia (LID).
Levodopa (L-DOPA) is highly efficient and is used to mitigate PD, but its prolonged use gives rise to motor abnormalities, including dyskinesia. Dyskinesia may be mild at first but may develop into a debilitating symptom and affect patients&rsquo; quality of life.
&nbsp;
<a href="https://www.delveinsight.com/report-store/parkinsons-disease-levodopa-induced-dyskinesia-pd-lid-epidemiology-forecast">Parkinson&rsquo;s disease Levodopa-induced Dyskinesia Epidemiology</a> Segmentation in the 7MM
<ul>
<li>Total cases of Parkinson&rsquo;s disease Levodopa-induced Dyskinesia</li>
<li>Type- specific cases of Parkinson&rsquo;s disease Levodopa-induced Dyskinesia</li>
</ul>
&nbsp;
Parkinson&rsquo;s disease Levodopa-induced Dyskinesia Epidemiological Insights Observed in the 7MM (2021)
The total diagnosed cases of Parkinson&rsquo;s disease Levodopa-induced Dyskinesia observed in the 7MM were observed to be 584,000 in the year 2021
&nbsp;
<a href="https://www.delveinsight.com/report-store/parkinsons-disease-levodopa-induced-dyskinesia-market">Parkinson&rsquo;s disease Levodopa-induced Dyskinesia Market Insight</a>
The market size of Parkinson&rsquo;s disease Levodopa-induced Dyskinesia in the 7MM is anticipated to increase to approximately USD 2300 Million by 2032.&nbsp;&nbsp;
Parkinson&rsquo;s disease Levodopa-induced Dyskinesia Market Strengths
The concept of &lsquo;drug-repurposing&rsquo; has been used in drug development for LID for many years, for instance, amantadine was initially licensed for viral infections, and clinical observation noted improved symptoms in PD subjects using the drug for influenza.
&nbsp;
Parkinson&rsquo;s disease Levodopa-induced Dyskinesia Market Opportunites
Improvements in the measurement of LID may emerge from technological advances, for instance, a wearable device easily worn by the patient at home that provides a measure of limb/trunk movement that correlates with LID level.
&nbsp;
Parkinson&rsquo;s disease Levodopa-induced Dyskinesia Emerging drugs
The emerging drugs in the Parkinson&rsquo;s disease Levodopa-induced Dyskinesia market are
<ul>
<li>KETARX (ketamine)</li>
<li>NLX-112 (befiradol)</li>
<li>JM-010</li>
<li>AV-101</li>
<li>Mesdopetam (IRL-790)</li>
<li>XADAGO (safinamide)</li>
<li>CPL500036 (CPL-36)</li>
</ul>
Parkinson&rsquo;s disease Levodopa-induced Dyskinesia key players
The key players working in the&nbsp; Parkinson&rsquo;s disease Levodopa-induced Dyskinesia market are
<ul>
<li>PharmaTher Inc</li>
<li>Neurolixis SAS/Gala laboratories</li>
<li>Bukwang Pharmaceutical/Contera Pharma</li>
<li>Vistagen</li>
<li>Ipsen Pharma</li>
<li>Newron Pharmaceuticals/Zambon Pharmaceuticals</li>
<li>Celon Pharma SA</li>
</ul>

Parkinson's Disease Levodopa-Induced Dyskinesia Market 

Parkinson's Disease Levodopa-Induced Dyskinesia Market Infographics 

Parkinson's disease levodopa-induced dyskinesia Market 

Parkinson's disease levodopa-induced dyskinesia Market    Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape